BiotechTube
Home/Pipeline/Enhanced Brain Delivery (EBD™) Platform

Enhanced Brain Delivery (EBD™) Platform

Neurodegenerative Diseases

PreclinicalResearch Stage

Key Facts

Indication
Neurodegenerative Diseases
Phase
Preclinical
Status
Research Stage
Company
Acumen Pharmaceuticals

About Acumen Pharmaceuticals

Acumen Pharmaceuticals is a public, clinical-stage biotech singularly focused on developing targeted Alzheimer's disease therapies based on the amyloid-beta oligomer (AβO) hypothesis. Its lead candidate, sabirnetug (ACU193), is a first-in-class monoclonal antibody in Phase 2 development, designed for high selectivity to soluble AβOs. The company has built a seasoned leadership team with deep Alzheimer's expertise, secured foundational IP from leading academic institutions, and is advancing a subcutaneous formulation and an Enhanced Brain Delivery platform. With Phase 2 enrollment complete, Acumen is positioned to generate critical efficacy data that could validate its differentiated scientific approach.

View full company profile

Therapeutic Areas

Alzheimer's DiseaseNeurodegenerative Diseases

Other Neurodegenerative Diseases Drugs

DrugCompanyPhase
UndisclosedModulo BioDiscovery
PBI-01207Phoenix BiotechnologyPre-clinical
Therapeutic Target Discovery PlatformValtedSeqDiscovery
Undisclosed Neurology Program(s)Base4Preclinical
Platform Application for Neurodegenerative DiseasesALTUCELLPre-clinical/Research
OGG1 Activator ProgramLuciole PharmaceuticalsPre-clinical
Lysosome Biology ProgramTalisman TherapeuticsPreclinical
Microglial Health ProgramTalisman TherapeuticsPreclinical
HSF1 Activator ProgramSisu PharmaPre-clinical
Platform-derived candidatesVRG TherapeuticsPre-clinical
Neurodegenerative Biomarkers R&DFiralisDevelopment
Neurodegeneration PipelineOrigenisPreclinical